浏览全部资源
扫码关注微信
不同细胞疗法治疗严重肢体缺血的系统评价和网状Meta分析 Δ
Systematic evaluation and network meta-analysis of different cell therapies in the treatment of critical limb ischemia
- 中国药房 2024年35卷第13期 页码：1634-1642
- 作者机构：
1.首都医科大学附属北京中医医院，北京 100010
2.北京市中医药研究所，北京 100010
- 作者简介：
住院医师，博士研究生。研究方向：周围血管病的研究与诊治。E-mail：1249326946@qq.com
主任医师，博士生导师，博士。研究方向：周围血管病的治疗。E-mail：xxying7341@126.com
- 基金信息：国家自然科学基金面上项目(82174388);北京市百千万人才工程培养经费资助项目(2019A30);第五批全国中医临床优秀人才研修项目(国中医药人教函〔2022〕1号);北京市医院管理中心“登峰”人才培养计划(DFL20220801)
DOI：10.6039/j.issn.1001-0408.2024.13.16
中图分类号： R973+.5;R269纸质出版日期：2024-07-15，
收稿日期：2023-12-16，
修回日期：2024-06-04，
- 稿件说明：
扫 描 看 全 文
蔺莉,徐旭英,洪雨欣.不同细胞疗法治疗严重肢体缺血的系统评价和网状Meta分析 Δ[J].中国药房,2024,35(13):1634-1642.
LIN Li,XU Xuying,HONG Yuxin.Systematic evaluation and network meta-analysis of different cell therapies in the treatment of critical limb ischemia[J].ZHONGGUO YAOFANG,2024,35(13):1634-1642.
蔺莉,徐旭英,洪雨欣.不同细胞疗法治疗严重肢体缺血的系统评价和网状Meta分析 Δ[J].中国药房,2024,35(13):1634-1642. DOI： 10.6039/j.issn.1001-0408.2024.13.16.
LIN Li,XU Xuying,HONG Yuxin.Systematic evaluation and network meta-analysis of different cell therapies in the treatment of critical limb ischemia[J].ZHONGGUO YAOFANG,2024,35(13):1634-1642. DOI： 10.6039/j.issn.1001-0408.2024.13.16.
摘要
目的
2
系统评价纯化的CD34
+
细胞（PCCs）、骨髓单核细胞（BMMNCs）、骨髓间充质干细胞（BMMSCs）和外周血单核细胞（PBMNCs）4种常见的细胞疗法在治疗严重肢体缺血（CLI）时的有效性和安全性。
方法
2
计算机检索PubMed、Scopus、Embase、Cochrane对照试验注册中心、Web of Science数据库，检索时限为各数据库建库起至2023年6月，收集PCCs、BMMNCs、BMMSCs和PBMNCs 4种不同细胞疗法对比其他细胞疗法或标准疗法（ST）治疗CLI的疗效和安全性的随机对照试验（RCT），结局指标包括截肢率、踝肱指数（ABI）、经皮氧分压（TCPO
2
）、溃疡愈合率、无痛步行距离（PFWD）和血管生成情况。提取符合纳入标准的临床研究资料，采用RoB 2.0工具进行偏倚风险评估，使用Stata 15.0软件进行统计分析。
结果
2
Meta分析共纳入22项研究，涉及 1 318名患者，治疗组涉及4种细胞疗法，分别是PCCs、BMMNCs、BMMSCs、PBMNCs。网状Meta分析显示，4种细胞疗法组截肢率均低于ST组，仅PBMNCs组差异具有统计学意义（
P
＜0.05）；4种细胞干预措施在提高ABI方面均优于ST组（
P
＜0.05），且BMMNCs对ABI的提高效果最显著；PBMNCs、BMMNCs组提高TCPO
2
方面与ST、BMMSCs相比差异有统计学意义（
P
＜0.05）；4种细胞干预措施在提高溃疡愈合率方面均优于ST，但BMMNCs组与ST组比较差异无统计学意义（
P
＞0.05），其余3组溃疡愈合率均显著高于ST组（
P
＜0.05），且PBMNCs组、BMMSCs组的溃疡愈合率显著高于BMMNCs组（
P
＜0.05）；BMMSCs移植后对患者PFWD的提高显著优于ST（
P
＜0.05），PBMNCs、BMMNCs组与ST组比较差异无统计学意义（
P
＞0.05）；BMMSCs、BMMNCs、PBMNCs这3种细胞疗法改善血管生成的效果均优于ST，且BMMSCs疗效显著优于BMMNCs和PBMNCs，差异均有统计学意义（
P
＜0.05）。
结论
2
4种细胞疗法都可以在不同程度上改善CLI患者的预后。PBMNCs移植后截肢率最低，且改善TCPO
2
和提高溃疡愈合率的效果最显著；BMMNCs改善ABI的效果最显著；在PFWD和血管生成方面，BMMSCs表现出明显的优势。
Abstract
OBJECTIVE
2
To systematically evaluate the efficacy and safety of the four most common cell therapies， namely purified CD34
+
（PCCs）， bone marrow mononuclear cells （BMMNCs）， bone marrow mesenchymal stem cells （BMMSCs） and peripheral blood mononuclear cells （PBMNCs） in the treatment of critical limb ischemia （CLI）.
METHODS
2
PubMed， Scopus， Embase， Cochrane Central Register of Controlled Trials （CENTRAL） and Web of Science databases were searched from the establishment of each database to June 2023 to collect randomized controlled trials （RCTs） comparing the efficacy and safety of four different cell therapies， namely PCCs， BMMNCs， BMMSCs and PBMNCs， with other cell therapies or standard therapy （ST） in the treatment of CLI. The outcomes indexes included amputation rate， ankle-brachial index （ABI）， transcutaneous oxygen partial pressure （TCPO
2
）， ulcer healing rate， pain-free walking distance （PFWD） and angiogenesis. After data extraction from clinical studies that met the inclusion criteria， the RoB 2.0 tool was used to assess the risk of bias， and Stata 15.0 software was used for statistical analysis.
RESULTS
2
Meta-analysis included 22 studies， involving 1 318 patients. The treatment groups involved 4 types of cell therapies， namely PCCs， BMMNCs， BMMSCs， and PBMNCs. Network meta-analysis showed that the amputation rates of the four cell therapies groups were lower than that of ST group， and only the difference in PBMNCs group was statistically significant（
P
＜0.05）. Four cell interventions were better than ST in improving ABI （
P
＜0.05）， and BMMNCs had the most significant effect on improving ABI. PBMNCs and BMMNCs groups had statistically significant differences in improving TCPO
2
， compared with ST group and BMMSCs group （
P
＜0.05）. Four cell interventions were better than ST in improving ulcer healing rate， among which BMMNCs group had no statistical difference with ST group （
P
＞0.05）； ulcer healing rates of the other three groups were higher than that of ST group （
P
＜0.05）， and those of PBMNCs and BMMSCs groups were significantly higher than that of BMMNCs group （
P
＜0.05）. BMMSCs group had a significantly better effect on improving the PFWD of patients than the ST group after transplantation， with statistical significance （
P
＜0.05）， but there was no significant difference in PBMNCs and BMMNCs groups compared with ST group （
P
＞0.05）. The three cell therapies of BMMSCs， BMMNCs and PBMNCs had a significantly better effect on angiogenesis than the ST group， and the BMMSCs group had a significantly better effect than the BMMNCs and PBMNCs groups， with statistical significance （
P
＜0.05）.
CONCLUSIONS
2
The four cell therapies can improve the prognosis of CLI patients to varying degrees. PBMNCs show the lowest amputation rate after transplantation and have the most significant effect on improving TCPO
2
and improving the ulcer healing rate. BMMNCs possess the most significant effect on improving ABI. BMMSCs represent obvious advantages in PFWD and angiogenesis.
关键词
细胞疗法严重肢体缺血外周动脉疾病单核细胞间充质干细胞CD34+细胞网状Meta分析
Keywords
critical limb ischemiaperipheral arterial diseasemononuclear cellsmesenchymal stem cellsCD34+ cellnetwork meta-analysis
references
FORSYTHE R O，BROWNRIGG J，HINCHLIFFE R J. Peripheral arterial disease and revascularization of the diabetic foot[J]. Diabetes Obes Metab，2015，17（5）：435-444.
FARBER A，EBERHARDT R T. The current state of critical limb ischemia：a systematic review[J]. JAMA Surg，2016，151（11）：1070-1077.
BEVAN G H，WHITE SOLARU K T. Evidence-based medical management of peripheral artery disease[J]. Arterioscler Thromb Vasc Biol，2020，40（3）：541-553.
BARNES J A，EID M A，CREAGER M A，et al. Epide- miology and risk of amputation in patients with diabetes mellitus and peripheral artery disease[J]. Arterioscler Thromb Vasc Biol，2020，40（8）：1808-1817.
PARIKH P P，LIU Z J，VELAZQUEZ O C. A molecular and clinical review of stem cell therapy in critical limb ischemia[J]. Stem Cells Int，2017，2017：3750829.
TERAA M，GREMMELS H，WIJNAND J G J，et al. Cell therapy for chronic limb-threatening ischemia：current evidence and future directions[J]. Stem Cells Transl Med，2018，7（12）：842-846.
JEYARAMAN M，NAGARAJAN S，MAFFULLI N，et al. Stem cell therapy in critical limb ischemia[J]. Cureus，2023，15（7）：e41772.
XIE B C，LUO H L，ZHANG Y S，et al. Autologous stem cell therapy in critical limb ischemia：a meta-analysis of randomized controlled trials[J]. Stem Cells Int，2018，2018：7528464.
LIU H，PAN T Y，LIU Y F，et al. The peripheral blood mononuclear cells versus purified CD34+ cells transplantation in patients with angiitis-induced critical limb ische- mia trial：5-year outcomes and return to work analysis：a randomized single-blinded non-inferiority trial[J]. Stem Cell Res Ther，2022，13（1）：116.
DUBSKÝ M，HUSÁKOVÁ J，BEM R，et al. Comparison of the impact of autologous cell therapy and conservative standard treatment on tissue oxygen supply and course of the diabetic foot in patients with chronic limb-threatening ischemia：a randomized controlled trial[J]. Front Endocrinol，2022，13：888809.
FANG G，JIANG X L，FANG Y，et al. Autologous periphe- ral blood-derived stem cells transplantation for treatment of no-option angiitis-induced critical limb ischemia：10-year management experience[J]. Stem Cell Res Ther，2020，11（1）：458.
DONG Z H，PAN T Y，FANG Y，et al. Purified CD34+ cells versus peripheral blood mononuclear cells in the treatment of angiitis-induced no-option critical limb ischaemia：12-month results of a prospective randomised single-blinded non-inferiority trial[J]. E Bio Med，2018，35：46-57.
LINDEMAN J H N，ZWAGINGA J J，KALLENBERG-LANTRUA G，et al. No clinical benefit of intramuscular delivery of bone marrow-derived mononuclear cells in non-reconstructable peripheral arterial disease：results of a phase-Ⅲ randomized-controlled trial[J]. Ann Surg，2018，268（5）：756-761.
HORIE T，YAMAZAKI S，HANADA S，et al. Outcome from a randomized controlled clinical trial ：improvement of peripheral arterial disease by granulocyte colony-stimulating factor-mobilized autologous peripheral-blood-mononuclear cell transplantation （IMPACT）[J]. Circ J，2018，82（8）：2165-2174.
PIGNON B，SEVESTRE M A，KANAGARATNAM L， et al. Autologous bone marrow mononuclear cell implantation and its impact on the outcome of patients with critical limb ischemia：results of a randomized，double-blind，placebo-controlled trial[J]. Circ J，2017，81（11）：1713-1720.
SKORA J，PUPKA A，JANCZAK D，et al. Combined autologous bone marrow mononuclear cell and gene therapy as the last resort for patients with critical limb ischemia[J]. Arch Med Sci，2015，11（2）：325-331.
TERAA M，SPRENGERS R W，SCHUTGENS R E，et al. Effect of repetitive intra-arterial infusion of bone marrow mononuclear cells in patients with no-option limb ische- mia：the randomized，double-blind，placebo-controlled rejuvenating endothelial progenitor cells via transcutaneous intra-arterial supplementation （JUVENTAS） trial[J]. Circulation，2015，131（10）：851-860.
LI M，ZHOU H，JIN X，et al. Autologous bone marrow mononuclear cells transplant in patients with critical leg ischemia：preliminary clinical results[J]. Exp Clin Transplant，2013，11（5）：435-439.
GUPTA P K，CHULLIKANA A，PARAKH R，et al. A double blind randomized placebo controlled phase Ⅰ/Ⅱ study assessing the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell in critical limb ischemia[J]. J Transl Med，2013，11：143.
OZTURK A，KUCUKARDALI Y，TANGI F，et al. Therapeutical potential of autologous peripheral blood mononuclear cell transplantation in patients with type 2 diabetic critical limb ischemia[J]. J Diabetes Complications，2012，26（1）：29-33.
LOSORDO D W，KIBBE M R，MENDELSOHN F，et al. A randomized，controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia[J]. Circ Cardiovasc Interv，2012，5（6）：821-830.
WALTER D H，KRANKENBERG H，BALZER J O，et al. Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia：a randomized-start，placebo-controlled pilot trial （PROVASA）[J]. Circ Cardiovasc Interv，2011，4（1）：26-37.
LU D B，CHEN B，LIANG Z W，et al. Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer：a double-blind，rando- mized，controlled trial[J]. Diabetes Res Clin Pract，2011，92（1）：26-36.
DASH N R，DASH S N，ROUTRAY P，et al. Targeting nonhealing ulcers of lower extremity in human through autologous bone marrow-derived mesenchymal stem cells[J]. Rejuvenation Res，2009，12（5）：359-366.
LU D B，JIANG Y Z，LIANG Z W，et al. Autologous transplantation of bone marrow mesenchymal stem cells on diabetic patients with lower limb ischemia supported by the clinical research fund of Southwest Hospital at Third Military Medical University （SWH2005A109）[J]. J Med Coll PLA，2008，23（2）：106-115.
HUANG P P，YANG X F，LI S Z，et al. Randomised comparison of G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow-mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans[J]. Thromb Haemost，2007，98（6）：1335-1342.
ARAI M，YU M S，NAGAI H，et al. Granulocyte colony-stimulating factor：a noninvasive regeneration therapy for treating atherosclerotic peripheral artery disease[J]. Circ J，2006，70（9）：1093-1098.
HUANG P P，LI S Z，HAN M Z，et al. Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes[J]. Diabetes Care，2005，28（9）：2155-2160.
TATEISHI-YUYAMA E，MATSUBARA H，MUROHARA T，et al. Therapeutic angiogenesis for patients with limb ischemia by autologous transplantation of bone-marrow cells：a pilot study and a randomised controlled trial[J]. Lancet，2002，360（9331）：427-435.
MATSUI K，MURAKAMI Y，YOSHIOKA T，et al. Therapeutic angiogenesis by transplantation of autologous bone marrow and peripheral blood mononuclear cells in patients with peripheral arterial disease[J]. Int J Angiol，2003，12（3）：155-161.
ZHOU B，BI Y Y，HAN Z B，et al. G-CSF-mobilized peripheral blood mononuclear cells from diabetic patients augment neovascularization in ischemic limbs but with impaired capability[J]. J Thromb Haemost，2006，4（5）：993-1002.
DE ANGELIS B，GENTILE P，ORLANDI F，et al. Limb rescue：a new autologous-peripheral blood mononuclear cells technology in critical limb ischemia and chronic ulcers[J]. Tissue Eng Part C Methods，2015，21（5）：423-435.
ISHIDA A，OHYA Y，SAKUDA H，et al. Autologous peripheral blood mononuclear cell implantation for patients with peripheral arterial disease improves limb ischemia[J]. Circ J，2005，69（10）：1260-1265.
0
浏览量
0
下载量
0
CSCD
- 网络PDF下载
- WORD下载
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 地址：重庆市渝中区大坪正街129号四环大厦8层 邮编：400042
- 技术支持由北京北大方正电子有限公司提供 渝ICP备15012710号
公网安备50010302001817 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies